- A partner tumor-infiltrating lymphocyte (TIL) program has advanced into pivotal-stage manufacturing at CTMC, demonstrating CTMC’s ability to support cell therapies from early development through registration-enabling production.
- CTMC has implemented a tailored digital chain-of-identity and chain-of-custody (COI/COC) system developed with Autolomous to support increased volumes of patient-specific manufacturing with robust end-to-end traceability.
- CTMC continues to expand its proprietary TIL platform, including TR-41, TR-56, and a closed manufacturing process designed to improve consistency, scalability, and commercial readiness for engineered TIL therapies.
Read the full release here: CTMC Advances into Pivotal Manufacturing